Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Chronic kidney disease and cardiovascular risk

Chronic kidney disease (CKD) encompasses abnormalities of kidney structure or function that persist for at least three months and have implications for health. It is a heterogeneous condition in its causes and course, associated with increased cardiovascular risk involving atherosclerosis, heart failure, arrhythmias, and sudden death. Its prognostic importance is not limited to the possibility of requiring dialysis: cardiovascular complications represent the main clinical problem in many patients.

Assessment requires two complementary dimensions: glomerular filtration rate and albuminuria. The former describes an excretory function, usually estimated using biomarkers; the latter indicates abnormal urinary albumin excretion, often associated with glomerular injury and vascular dysfunction. Risk increases as either becomes abnormal and when both coexist, but the cause of kidney disease, age, duration, trajectory, and pre-existing heart disease modify individual interpretation.

The relationship between heart and kidney is bidirectional. Kidney disease promotes hypertension, congestion, and myocardial injury; heart failure can impair kidney function through venous congestion, reduced perfusion, and neurohormonal activation. Distinguishing chronic disease, hemodynamic changes, and acute injury helps avoid both underestimating deterioration and inappropriately stopping protective therapy.

Etiology and cardiovascular pathophysiology

Diabetes and hypertension are common settings for kidney injury, but etiological diagnosis also encompasses glomerular diseases, tubulointerstitial disorders, inherited conditions, obstruction, and vascular disease. Their presence cannot be inferred from creatinine alone. Rapidly progressive kidney disease, significant hematuria, or systemic features require a different approach from a slow, stable reduction in filtration.

Conventional factors, including blood pressure, diabetes, and lipoproteins, contribute to risk and often precede kidney disease. As function declines, factors specific to the uremic milieu are added. Atherosclerosis remains important but does not explain all events: the relative contribution of heart failure, arrhythmias, and sudden death increases in advanced stages and during kidney replacement therapy.

Reduced ability to excrete sodium and water promotes volume overload, higher blood pressure, and increased ventricular workload. Activation of the renin–angiotensin–aldosterone and sympathetic nervous systems sustains vasoconstriction and remodeling. Ventricular hypertrophy may progress to stiffness and diastolic dysfunction, while ischemia and other cardiac diseases can add systolic impairment. The same increase in body weight may therefore represent congestion, adiposity, or both.

Renal venous congestion can reduce the effective perfusion gradient and contribute to a declining filtration rate in heart failure. The problem is not always due to low cardiac output. A rise in creatinine during treatment requires assessment of blood pressure, volume status, urine output, and the overall course: successful decongestion and persistent kidney injury are not interchangeable phenomena, although they may coexist.

Uremic toxins, oxidative stress, and inflammation can affect the endothelium, smooth muscle, myocardium, and immune system. Microvascular dysfunction reduces perfusion reserve and may contribute to ischemia even without critical epicardial stenoses. Interstitial fibrosis and changes in myocardial metabolism contribute to the phenotype of kidney disease-associated cardiomyopathy, which is often multifactorial.

Changes in mineral metabolism include alterations in phosphate, calcium, parathyroid hormone, and mediators such as FGF23 and Klotho. They can promote vascular cell transformation and medial arterial calcification, increasing arterial stiffness and pulsatile load. Intimal calcification within plaques and medial calcification may coexist but have different implications; vascular calcium is not a perfect measure of luminal stenosis.

Valvular calcification, especially of the aortic valve and mitral annulus, adds to cardiac loading and may progress in advanced stages. Hypertension, arteriosclerosis, and mineral abnormalities interact, but simply lowering a biomarker does not automatically establish a mortality reduction. Management of mineral disorders takes multiple measures and the clinical picture into account, avoiding the conversion of biological associations into unproven therapeutic benefits.

Anemia may result from inadequate erythropoietin production, iron deficiency, inflammation, blood loss, or other causes. By reducing oxygen-carrying capacity, it can worsen fatigue and cardiac workload. However, not all anemia in a patient with kidney disease is caused by kidney disease, and normalizing hemoglobin with erythropoiesis-stimulating agents does not equate to protecting the heart; treatment targets must account for risks.

Arrhythmic risk arises from interactions among fibrosis, hypertrophy, ischemia, and autonomic and electrolyte disturbances. Potassium, calcium, and magnesium can affect conduction and repolarization. In hemodialysis patients, changes in volume and solute levels add acute fluctuations to a vulnerable substrate. Sudden death therefore cannot be interpreted solely as a consequence of an unstable coronary plaque.

Kidney disease also alters hemostatic balance: thrombotic risk and a predisposition to bleeding can coexist, particularly in advanced stages. Drug accumulation, platelet dysfunction, anemia, and procedures modify the balance. Greater ischemic risk does not justify indiscriminately intensifying antiplatelet or anticoagulant treatment; each indication requires specific evaluation and dosing appropriate to kidney function.

Clinical manifestations, history, and physical examination

Early stages may be asymptomatic and recognized during assessment of hypertension, diabetes, or cardiovascular risk. Normal urine output does not exclude a reduced filtration rate. Nocturia, edema, or fatigue may be signs but are nonspecific; uremic manifestations and reduced functional capacity can emerge in advanced stages.

History-taking reconstructs trends in test results, acute kidney injury episodes, infections, obstructions, family history, and systemic diseases. Nonsteroidal anti-inflammatory drugs, nonprescription products, and previous nephrotoxic exposures must be considered. A diagnosis of diabetes or hypertension should not prevent recognition of an additional renal cause, especially when the course is atypical.

Cardiovascular history explores dyspnea, angina, and syncope, edema, rapid weight gain, claudication, and previous events. Ischemia and heart failure may present with nonspecific symptoms, while anemia and limited mobility may mask exertional limitation. Recent chest pain or respiratory deterioration must not automatically be attributed to “high creatinine.”

Examination assesses volume status, blood pressure measured using appropriate technique, possible orthostatic changes, rhythm, jugular venous distension, lung findings, and peripheral pulses. Edema and crackles are not always present together, and examination must be integrated with weight, urine output, and clinical course. In patients receiving dialysis, the timing relative to sessions, reference weight, and characteristics of vascular access are relevant.

Assessment of nutrition and frailty is part of risk evaluation. Muscle loss, poor intake, and inflammation may lower creatinine, making estimated filtration appear more favorable than it actually is. In older patients, disability and fall risk affect blood pressure targets and tolerability of combination treatments. Prognosis is not adequately defined by a single laboratory threshold.

Kidney diagnosis and classification

Diagnosis requires an eGFR below 60 mL/min/1.73 m² or markers of kidney damage persisting for at least three months. These include albuminuria, urinary sediment abnormalities, structural or histological changes, and other recognized conditions. An eGFR of 60 or higher without evidence of damage is insufficient by itself to establish CKD. Conversely, a single low result requires clarification of chronicity, context, and possible acute causes.

GFR staging distinguishes G1 with eGFR at least 90, G2 from 60 to 89, G3a from 45 to 59, G3b from 30 to 44, G4 from 15 to 29, and G5 below 15 mL/min/1.73 m². G1 and G2 constitute chronic kidney disease only when other criteria of damage are present. G5 identifies very advanced kidney failure, but starting dialysis does not follow mechanically from crossing a single numerical threshold.

Albuminuria is classified using the urine albumin-to-creatinine ratio: A1 below 30 mg/g, A2 from 30 to 300 mg/g, and A3 above 300 mg/g. A first-morning sample is often preferable for confirmation. Strenuous exercise, infection, fever, hematuria, and heart failure can transiently alter the result; testing should be repeated and interpreted when necessary. A negative urine dipstick does not always exclude a clinically significant increase.

The CGA classification integrates cause, GFR category, and albuminuria category. Their combination describes prognosis better than creatinine alone, without replacing longitudinal observation. Marked albuminuria can indicate risk even with relatively preserved GFR; a stable reduction in older age requires individualized judgment but is not automatically deprived of clinical significance.

Creatinine-based estimation depends on muscle production, diet, tubular secretion, and medications. Validated equations are used with recognition of their limitations in amputations, cachexia, extreme muscle mass, or acute changes. When greater accuracy would alter a decision, combined creatinine–cystatin C estimation or direct GFR measurement can improve assessment. Cystatin C is also affected by nonrenal factors and is not an infallible reference.

Further investigations include urinalysis and ultrasound, with immunological tests, genetic assessment, or biopsy according to suspicion. Glomerular hematuria, substantial proteinuria, rapid decline, or systemic signs warrant specialist attention. Ultrasound can document obstruction, anatomical abnormalities, or features of chronicity; however, preserved kidney size does not exclude significant kidney disease.

Cardiovascular investigations and prognostic stratification

Risk assessment integrates kidney stage and heart disease, previous events, diabetes, blood pressure, lipids, and smoking. Common general-population models may underrepresent some components of kidney disease and should not be applied outside their intended scope. Models predicting progression to kidney failure, such as the Kidney Failure Risk Equation in appropriate patients, answer a different question from predicting myocardial infarction or heart failure.

Laboratory testing evaluates electrolytes, anemia, and metabolic abnormalities according to stage and treatment. Blood counts, iron studies, potassium, and bicarbonate may identify factors worsening symptoms or medication safety; calcium, phosphate, and parathyroid hormone are interpreted together and over time when indicated. Correcting a value requires understanding its cause and consequences, avoiding interventions based on the number alone.

ECG and echocardiography are selected to assess rhythm, hypertrophy, ventricular function, valves, and pressures when clinically indicated. BNP and NT-proBNP may be higher when filtration is reduced, but retain information to be integrated with symptoms and cardiac structure. No universal correction transforms every result into a value equivalent to that in a person with normal kidney function.

Troponins may be persistently elevated in CKD, especially in advanced disease. This does not justify ignoring a possible myocardial infarction: serial changes, clinical presentation, ECG, and imaging help distinguish chronic from acute injury. Elevated concentrations are not necessarily due solely to reduced clearance, nor does a single elevated result by itself establish acute coronary syndrome.

The choice of coronary imaging considers symptoms, probability, calcification, kidney function, and therapeutic consequences. Extensive calcification can limit some anatomical tests; functional tests answer different questions. When contrast medium is needed, the risk of acute injury, volume status, medications, and options to reduce exposure are assessed. Preventive hydration, when indicated, must be tailored to heart failure and not indiscriminately given to a congested patient.

In ISCHEMIA-CKD, an initial invasive strategy in stable coronary disease with advanced kidney disease and moderate or severe ischemia did not reduce the composite of death or myocardial infarction compared with an initially conservative strategy. This finding does not apply to the need to treat acute coronary syndrome or other scenarios excluded from the trial. It encourages linking procedures to expected benefit rather than treating a positive ischemia test as an automatic indication for everyone.

Evaluation for peripheral artery disease starts with symptoms, pulses, and limb lesions. Medial calcification can make arteries incompressible and produce a falsely high ankle–brachial index; toe pressures and additional techniques can clarify the situation. An ulcer in a patient with kidney disease and diabetes requires attention to ischemia, neuropathy, and infection together, as these may progress without proportional pain.

Treatment and cardiorenal protection

Management combines etiological treatment and prevention. Treating a glomerular disorder or relieving an obstruction does not replace cardiovascular risk control; likewise, good blood pressure does not make a renal diagnosis unnecessary. The plan incorporates diet, physical activity compatible with functional capacity, smoking cessation, and adiposity management while preserving nutrition and muscle mass. Restrictions on sodium, protein, potassium, or fluids require individualized indications rather than being imposed at every stage.

Blood pressure control lowers risk and requires reliable measurements. KDIGO 2021 proposes systolic blood pressure below 120 mmHg, when tolerated and measured using a standardized office protocol, in appropriate adults with hypertension and nondialysis CKD. This target must not be applied mechanically to an occasional reading. The 2024 ESC guidelines identify a range of 120–129 mmHg for many treated adults; measurement method, frailty, orthostasis, and clinical conditions must be made explicit when choosing the target.

ACE inhibitors and angiotensin receptor blockers play a central role in albuminuric kidney disease and specific cardiac conditions. They are used at tolerated doses, with creatinine and potassium monitored after initiation or dose increases, generally within two to four weeks depending on risk. A substantial increase in creatinine, for example more than 30% in the first weeks, warrants assessment of volume, medications, and possible hemodynamic or renovascular causes. An eGFR falling below 30 is not in itself a reason for discontinuation.

Routine dual blockade with an ACE inhibitor and an angiotensin receptor blocker is avoided as a way to achieve a larger reduction in albuminuria because of adverse effects. Hyperkalemia requires review of intake, medications, acidosis, and renal function; in selected patients, diuretics or potassium binders can help maintain beneficial therapies. Severity and speed of onset determine urgency; planned follow-up should not be awaited when there is an arrhythmic risk.

SGLT2 inhibitors offer organ protection beyond diabetes. KDIGO 2024 recommends their use in adults with CKD and eGFR at least 20 mL/min/1.73 m² with albuminuria of at least 200 mg/g, or with heart failure regardless of albuminuria; in type 2 diabetes with CKD, indications cover a broader setting. For eGFR 20–45 and albuminuria below 200 mg/g, the recommendation is weaker. The particular agent, authorization, and individual clinical picture complete the decision.

In DAPA-CKD, dapagliflozin reduced the primary composite renal and cardiovascular outcome in people with albuminuric CKD, with and without diabetes: events occurred in 9.2% versus 14.5% with placebo over a median 2.4-year follow-up. Benefits were also documented for other prespecified outcomes. The selected study population and composite endpoint definition must accompany these numbers, which are not universal estimates for every kidney disease.

EMPA-KIDNEY enrolled a broader population in terms of eGFR and albuminuria and showed a reduction in kidney disease progression or cardiovascular death with empagliflozin. Benefit for the composite does not mean a statistically demonstrated reduction in each component or every secondary outcome: the trial did not find a significant difference for hospitalization for heart failure or cardiovascular death considered together. This distinction allows use of the evidence without attributing findings to a single study that it did not establish.

A hemodynamic fall in GFR, generally reversible, may occur on starting treatment and must be distinguished from progressive injury. Volume status, blood pressure, and combination with diuretics require attention; prolonged fasting, surgery, or critical illness may prompt temporary interruption because of the risk of ketosis. A sick-day management plan must also include appropriate resumption of medication. The evidence does not justify indiscriminately starting these drugs in dialysis or extending their use to type 1 diabetes.

In albuminuric CKD with type 2 diabetes, finerenone may provide additional benefit in patients with compatible GFR and potassium levels who are already receiving guideline-directed treatment, as documented in the FIDELIO-DKD program. Potassium monitoring is essential; the absence of a need for glucose lowering does not negate the rationale. GLP-1 receptor agonists with relevant evidence are another option: FLOW documented favorable renal outcomes with semaglutide in a defined diabetic population. These findings should not be extended to every cause of CKD without assessing applicability.

Lowering atherogenic lipoproteins is indicated in many patients with nondialysis CKD. In KDIGO guidance, age at least 50 years and kidney disease often support prescribing a statin or statin plus ezetimibe, whereas in younger patients vascular disease, diabetes, and risk are considered. European treatment targets depend on the overall cardiovascular risk category. Kidney function, interactions, and tolerability guide agent and dose, without treating every reduction in GFR as a contraindication to statins.

The SHARP study showed that simvastatin combined with ezetimibe reduces major atherosclerotic events in CKD. Dialysis, however, requires specific interpretation of the evidence: 4D and AURORA did not demonstrate significant benefit for their respective primary composite endpoints when statins were initiated in patients already receiving hemodialysis. Guidelines therefore distinguish routine initiation during dialysis from continuation of existing treatment and individual indications. High cardiovascular risk alone does not make treatment response identical at every stage.

Heart failure treatment retains therapies with demonstrated benefit according to ejection fraction and the clinical picture, adjusting doses and monitoring to kidney function. Diuretics treat congestion and may require different combinations or doses when function is reduced; response is tracked through weight, symptoms, urine output, and electrolytes. Kidney disease should not automatically mean abandoning every effective cardiac treatment, but it requires proportionate surveillance and shared management of tolerability limits.

Antithrombotic therapy is selected for actual indications, such as secondary prevention, atrial fibrillation, or thromboembolism. CKD alone does not make aspirin universal for primary prevention. For anticoagulants, the drug-specific method of estimating kidney function must be followed, which may differ from eGFR used for staging; doses, interactions, and dialysis require particular caution. Bleeding risk does not eliminate embolic risk, but makes an explicit balance essential.

Treatment of anemia follows its cause, iron availability, symptoms, and the need to avoid transfusions, in accordance with updated KDIGO recommendations. Indiscriminate normalization of hemoglobin with erythropoiesis-stimulating agents is not pursued to prevent cardiovascular events. Similarly, managing mineral disorders considers trends in calcium, phosphate, and parathyroid hormone and possible adverse effects, without automatically attributing a survival benefit to correction of an individual parameter.

In advanced disease, preparation for kidney replacement therapy, volume control, and choice of vascular access require nephrology–cardiology coordination. A high-flow arteriovenous access may contribute to overload in susceptible people; a causal relationship must be documented before modifying it. Dialysis and transplantation change the therapeutic setting but do not erase accumulated cardiovascular disease or make prevention unnecessary.

Prognosis and complications

Prognosis reflects the combination of cause, stage, and trajectory with cardiovascular risk. Increasing albuminuria, rapid GFR decline, hospitalizations for heart failure, and new ischemic events indicate a need to reassess management. Apparently stable creatinine may be less reassuring when muscle loss is present; longitudinal assessment must include function and nutrition, not only numbers.

Complications include myocardial infarction, stroke, and limb ischemia, as well as recurrent congestion, arrhythmias, valve disease, and sudden death. In uremic stages, pericardial involvement may occur and must be distinguished from other causes of pain and effusion. An acute electrolyte disorder can make urgent a situation that otherwise appeared chronically stable.

Care-related complications include acute kidney injury and drug toxicity, hypotension, hyperkalemia, and bleeding. Prevention requires updating prescriptions as filtration, weight, or clinical status changes, avoiding both accumulation and unjustified interruptions. A coordinated strategy that protects kidney, heart, and independence at the same time offers a better chance of changing the course than isolated control of a single target.

References
  1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International. 2024;105(4S):S117–S314.
  2. Webster AC et al. Chronic Kidney Disease. The Lancet. 2017;389(10075):1238–1252.
  3. Matsushita K et al. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nature Reviews Nephrology. 2022;18(11):696–707.
  4. Ndumele CE et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606–1635.
  5. Visseren FLJ et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021;42(34):3227–3337.
  6. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney International. 2021;99(3S):S1–S87.
  7. McEvoy JW et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. European Heart Journal. 2024;45(38):3912–4018.
  8. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney International Supplements. 2017;7(1):1–59.
  9. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD). Kidney International. 2026;109(1S):S1–S99.
  10. Mach F et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal. 2025;46(42):4359–4378.
  11. American Diabetes Association Professional Practice Committee for Diabetes. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S246–S260.
  12. Heerspink HJL et al. Dapagliflozin in Patients with Chronic Kidney Disease. The New England Journal of Medicine. 2020;383(15):1436–1446.
  13. EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. The New England Journal of Medicine. 2023;388(2):117–127.
  14. Bakris GL et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. The New England Journal of Medicine. 2020;383(23):2219–2229.
  15. Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. The New England Journal of Medicine. 2024;391(2):109–121.
  16. Baigent C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. The Lancet. 2011;377(9784):2181–2192.
  17. Wanner C et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. The New England Journal of Medicine. 2005;353(3):238–248.
  18. Fellström BC et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. The New England Journal of Medicine. 2009;360(14):1395–1407.
  19. Bangalore S et al. Management of Coronary Disease in Patients with Advanced Kidney Disease. The New England Journal of Medicine. 2020;382(17):1608–1618.
  20. Vrints C et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. European Heart Journal. 2024;45(36):3415–3537.
  21. Mazzolai L et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. European Heart Journal. 2024;45(36):3538–3700.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.